基本信息
views: 23
Career Trajectory
Bio
I am a Founder of Zylem Biosciences and the Vice President of Operations. I manage and oversee the development of our lead program, focused on ZYL-001 for cancers dependent upon cholesterol uptake. My expertise is on synthesizing bio-nanomaterials that seamlessly interface with biological systems. I am proficient in nanoparticle synthesis, characterization, in vitro and in vivo assay development, and have spent years developing of ZYL-001. Further, I have become knowledgeable in scaled manufacturing, drug product formulation, and regulatory compliance, all areas necessary to accelerate ZYL-001 to the clinic. I appreciate how important it is to collaborate and build a team of highly trained experts to develop ZYL-001 into a transformative clinical therapy, and thus have leaned on and learned from experts on our board, as well as experts at institutions outside our organization. Prior to graduate school, I worked with Dr. C. Shad Thaxton, at Northwestern University as he was establishing his laboratory, where upon I was responsible for complete set up and operation of his lab. I soon transitioned to graduate school at Northwestern where I continued my scientific research with Dr. Thaxton. My thesis work focused on the development of a nucleic acid delivery vehicles that were inspired by natural nanostructures, like lipoproteins. Much of this work laid the foundation in the field of nanoparticle nucleic acid delivery and key concepts I developed have translated to the new vaccine technology. Additionally, I worked closely with the NIH Nanotechnology Characterization Lab (NCL), to characterize and assess ZYL-001 in in vitro and in vivo models, including safety and pharmacokinetic/dynamics assays. Further, I worked on multiple lipid nanoparticle projects and through several collaborations and intra-laboratory projects I have closely advised students, post-docs, residents, and educated facility in and outside our field of research. After graduate school Dr. Thaxton and I co-founded Zylem Biosciences. Much of the intellectual property we co-developed in his laboratory has been licensed into Zylem. At Zylem we have focused our efforts on our lead program to develop ZYL-001 therapy to treat cholesterol uptake and redox addicted cancers.
Research Interests
Papers共 50 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cited0Views0Bibtex
0
0
Stephen E Henrich,Kaylin M McMahon,Michael P Plebanek,Andrea E Calvert, Timothy J Feliciano, Samuel Parrish,Fabio Tavora,Anthony Mega,Andre De Souza,Benedito A Carneiro,C Shad Thaxton
Poster Presentations - Proffered Abstracts (2020)
biorxiv(2020)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn